BSE · 512217
Prism Medico & Pharmacy Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹0 Cr with net profit ₹-0 Cr — a -85.71% net margin, versus -14.29% the period before.
Shareholding
As of 2026-06-30
- Promoter29.98%
- Public70.02%
4,177 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.76× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — GSM · GSM 0. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Trading · ranked #279 of 666 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Enterprises Limited | ₹4,09,340 Cr | 24.35 | 4.32 | 3.42% | 9.3% |
| Avenue Supermarts Limited | ₹2,50,991 Cr | 381.38 | 10.26 | 12.14% | 4.29% |
| Trent Ltd. | ₹1,60,247 Cr | 92.84 | 22.94 | 24.62% | 8.57% |
| FSN E-Commerce Ventures Ltd. | ₹93,790 Cr | 1212.96 | 65.21 | 13.87% | 1.99% |
| Vishal Mega Mart Limited | ₹50,703 Cr | 56.97 | 6.83 | 11.32% | 6.61% |
| Premier Energies Limited | ₹47,038 Cr | 102.19 | 10.9 | 35.05% | 19.3% |
| Aegis Logistics Limited | ₹45,019 Cr | 109.72 | 7.44 | 14.83% | 10.78% |
| Aditya Infotech Limited | ₹40,364 Cr | 238.34 | 21.48 | 19.61% | 8.72% |
| Redington Limited | ₹22,472 Cr | 57.38 | 2.21 | 14.67% | 1.25% |
| Honasa Consumer Limited | ₹14,620 Cr | 210.96 | 10.36 | 14.16% | 8.36% |
| Prism Medico & Pharmacy Ltd.(this company) | ₹39 Cr | 123.52 | 1.68 | 2.07% | 13.52% |
AI analysis
AI-generated · google/gemini-2.5-flashPrism Medico & Pharmacy Ltd. is listed with a market capitalization of Rs 40 Cr. The company has a PE ratio of 127.39 and an EPS of 0.23. The return on equity (ROE) is 206.6%, while the return on capital employed (ROCE) is 2.809%. The debt-to-equity ratio stands at 0.17. The profit margin is 13.52%.
Positives
- +The debt-to-equity ratio is low at 0.17.
- +The return on equity (ROE) is 206.6%, indicating efficient use of shareholder funds.
- +The profit margin is 13.52%.
Negatives
- −The company has reported negative net profit in three of the last five available quarters: -0.24 Cr in Mar 2026, -0.01 Cr in Dec 2025, and -0.08 Cr in Sept 2025.
- −The promoter shareholding is 30.1978%, which is below 50%.
- −The company is under GSM surveillance, which indicates regulatory scrutiny.
- −The number of shareholders increased significantly from 1160 in Dec 2016 to 4300 in May 2026, which may imply increased public interest and speculative activity without corresponding fundamental growth.
Financial Performance
The company reported revenue of Rs 0.28 Cr for the quarter ending Mar 2026, with a net profit of -0.24 Cr. For the quarter ending Dec 2025, revenue was Rs 0.07 Cr with a net profit of -0.01 Cr. In the Sept 2025 quarter, revenue was Rs 0.5 Cr, leading to a net profit of -0.08 Cr. The June 2025 quarter saw a revenue of Rs 1.59 Cr and a net profit of Rs 0.66 Cr. The earliest available quarterly data for Mar 2025 shows revenue of Rs 0.07 Cr and a net profit of Rs 0.04 Cr.
Profitability & Returns
Prism Medico & Pharmacy Ltd. has a profit margin of 13.52%. The return on equity (ROE) is 206.6%. The return on capital employed (ROCE) stands at 2.809%. The EPS is 0.23. The company's PE ratio is 127.39 which indicates its market valuation relative to its earnings per share.
Balance Sheet
The company maintains a debt-to-equity ratio of 0.17, indicating a relatively low reliance on debt financing. The book value per share is Rs 16.89. No further details regarding assets or liabilities are provided in the available data.
Ownership & Pledges
Public shareholding stands at 69.8022%. There is no promoter pledging reported (0%). There are zero holdings by DIIs and FIIs. The total number of shareholders is 4300.
Regulatory & Surveillance
The company is under GSM surveillance as indicated by 'GSM · GSM 0' with 'GSM' measures. This suggests that the stock is subject to regulatory scrutiny for reasons such as abnormal price variations, low liquidity, or other operational issues.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Prism Medico & Pharmacy Ltd.share price & fundamentals